Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -124.08
- Piotroski Score 2.00
- Grade N/A
- Symbol (PMN)
- Company ProMIS Neurosciences, Inc.
- Price $1.23
- Changes Percentage (-1.6%)
- Change -$0.02
- Day Low $1.22
- Day High $1.30
- Year High $3.10
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/12/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.68
- Trailing P/E Ratio -2.6
- Forward P/E Ratio -2.6
- P/E Growth -2.6
- Net Income $-13,212,482
Income Statement
Quarterly
Annual
Latest News of PMN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Concerns Surrounding Phoenix Mecano's (VTX:PMN) Performance
Phoenix Mecano AG's profit numbers were in line with expectations, but unusual items contributed to a significant gain. This may not be sustainable, potentially impacting future profitability. Shareho...
By Yahoo! Finance | 1 month ago -
With EPS Growth And More, Phoenix Mecano (VTX:PMN) Makes An Interesting Case
Investors often seek 'the next big thing', leading to risky investments in loss-making companies. However, focusing on profitable companies like Phoenix Mecano can provide long-term value. With growin...
By Yahoo! Finance | 1 month ago